COMING EVENTS

2020 AACBS Annual General Meeting and Scientific Meeting will be hosted online in September 2020. Stay tuned!                        

 
Newsletter
*Email
Name


GO
 
Prof. Chao Deng, PhD

 

Professor Chao Deng, PhD

School of Medicine, University of Wollongong 

Head, Antipsychotic Research Laboratory

Illawarra Health and Medical Research Institute

University of Wollongong

Prof Chao Deng was awarded a PhD in Neuroscience and Behaviour at the University of New England in 1999 and completed his postdoctoral training at the University of New South Wales. Currently he is a Professor in School of Medicine, University of Wollongong and Head of the Antipsychotic Research Laboratory in the Illawarra Health and Medical Research Institute. Prof Deng is a leading expert in the neuropharmacology of antipsychotic drugs, in which his research has been continually funded by NHMRC grants.

 

 

Mental disorders are the largest overall cause of disability worldwide, and antipsychotic drugs are widely used to control various mental disorders, such as schizophrenia, bipolar disorder, dementia, and major depression. However, currently-used antipsychotics have only limited efficacy, and cause some serious metabolic side-effects such as obesity, diabetes and hyperlipidaemia. Although antipsychotics were developed to treat schizophrenia in adults, they have been widely and increasingly used (“off label”) in children, without understanding the long-tern consequences. Prof Deng’s laboratory is currently investigating (1) the neuropharmacological mechanisms underlying the therapeutics and metabolic side-effects of antipsychotic drugs; and (2) how early antipsychotic exposures in children affect neurotransmission and behaviours in adults (recently reported by ABC National News: http://www.abc.net.au/news/2016-06-22/pyschotic-medication-for-children-could-have-lasting-effects/7530340 ). His laboratory is also studying (3) the pathophysiology of schizophrenia, and (4) the animal models of schizophrenia. Their research leads to develop new treatment strategies for improving clinical efficacy and reducing side-effects (such as obesity and diabetes) of antipsychotic drugs.